Vanderbilt Heart and Vascular Institute, Nashville, Tennessee.
Vanderbilt Heart and Vascular Institute, Nashville, Tennessee.
Heart Rhythm. 2018 Jan;15(1):56-62. doi: 10.1016/j.hrthm.2017.09.006. Epub 2017 Sep 14.
Catheter ablation is now a mainstay of therapy for ventricular arrhythmias (VAs). However, there are scenarios where either physiological or anatomical factors make ablation less likely to be successful.
The purpose of this study was to demonstrate that cardiac sympathetic denervation (CSD) may be an alternate therapy for patients with difficult-to-ablate VAs.
We identified all patients referred for CSD at a single center for indications other than long QT syndrome and catecholaminergic polymorphic ventricular tachycardia who had failed catheter ablation. Medical records were reviewed for medical history, procedural details, and follow-up.
Seven cases of CSD were identified in patients who had failed prior catheter ablation or had disease not amenable to ablation. All patients had VAs refractory to antiarrhythmic drugs, with a median arrhythmia burden of 1 episode of sustained VA per month. There were no acute complications of sympathectomy. One of 7 patients (14%) underwent heart transplant. No patient had sustained VA after sympathectomy at a median follow-up of 7 months.
Because of anatomical and physiological constraints, many VAs remain refractory to catheter ablation and remain a significant challenge for the electrophysiologist. While CSD has been described as a therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia, data regarding its use in other cardiac conditions are sparse. This series illustrates that CSD may be a viable treatment option for patients with a variety of etiologies of VAs.
导管消融术现已成为治疗室性心律失常(VA)的主要方法。然而,在某些情况下,生理或解剖因素会降低消融术的成功率。
本研究旨在证明心脏去交感神经术(CSD)可能是一种治疗难以消融的 VA 的替代疗法。
我们在一家单中心确定了所有因除长 QT 综合征和儿茶酚胺多形性室性心动过速以外的适应症而接受 CSD 的患者,这些患者在导管消融术失败后被转诊。回顾了病历以获取病史、手术细节和随访信息。
在导管消融术失败或疾病不适合消融的患者中,共确定了 7 例 CSD。所有患者均有抗心律失常药物难治性 VA,心律失常负担中位数为每月 1 次持续性 VA。交感神经切除术无急性并发症。7 例患者中有 1 例(14%)接受了心脏移植。在中位随访 7 个月时,所有患者在交感神经切除术后均无持续性 VA。
由于解剖和生理限制,许多 VA 仍然对导管消融术有抵抗力,仍然是电生理学家的重大挑战。虽然 CSD 已被描述为长 QT 综合征和儿茶酚胺多形性室性心动过速的治疗方法,但关于其在其他心脏疾病中的应用的数据很少。本系列研究表明,CSD 可能是治疗各种 VA 病因的可行治疗选择。